Share on StockTwits
 

ANI Pharmaceuticals (NASDAQ:ANIP) released its earnings data on Tuesday. The company reported $0.35 EPS for the quarter, American Banking News.com reports. The company had revenue of $10.53 million for the quarter, compared to the consensus estimate of $5.32 million.

ANIP has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of ANI Pharmaceuticals to a “neutral” rating in a research note on Friday, January 24th. They now have a $23.90 price target on the stock. On a related note, analysts at Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, January 22nd. They set an “outperform” rating and a $29.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $27.00 price target on the stock.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at 21.47 on Tuesday. ANI Pharmaceuticals has a one year low of $4.80 and a one year high of $25.75. The stock’s 50-day moving average is $21.48 and its 200-day moving average is $13.17. The company’s market cap is $203.5 million.

ANI Pharmaceuticals, Inc, formerly BioSante Pharmaceuticals, Inc, is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.